Evoke Pharma Inc (NASDAQ:EVOK) – Equities researchers at B. Riley reduced their Q1 2018 EPS estimates for Evoke Pharma in a research note issued on Thursday. B. Riley analyst D. Buck now anticipates that the specialty pharmaceutical company will earn ($0.19) per share for the quarter, down from their previous forecast of ($0.10). B. Riley currently has a “Buy” rating and a $5.00 target price on the stock. B. Riley also issued estimates for Evoke Pharma’s Q2 2018 earnings at ($0.16) EPS, Q3 2018 earnings at ($0.06) EPS, Q4 2018 earnings at ($0.02) EPS, FY2018 earnings at ($0.40) EPS, FY2019 earnings at ($0.83) EPS, FY2020 earnings at $0.10 EPS and FY2021 earnings at $0.85 EPS.
Other research analysts also recently issued reports about the company. Zacks Investment Research upgraded Evoke Pharma from a “hold” rating to a “buy” rating and set a $2.25 target price for the company in a research report on Thursday, March 8th. HC Wainwright set a $9.00 target price on Evoke Pharma and gave the company a “buy” rating in a research report on Wednesday, November 29th. Finally, ValuEngine downgraded Evoke Pharma from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $7.66.
Evoke Pharma (NASDAQ:EVOK) last posted its earnings results on Wednesday, March 7th. The specialty pharmaceutical company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.21.
A number of large investors have recently added to or reduced their stakes in the stock. Sphera Funds Management LTD. raised its holdings in Evoke Pharma by 34.7% during the 4th quarter. Sphera Funds Management LTD. now owns 769,149 shares of the specialty pharmaceutical company’s stock valued at $1,738,000 after buying an additional 198,127 shares during the period. Vanguard Group Inc. raised its holdings in Evoke Pharma by 15.1% during the 2nd quarter. Vanguard Group Inc. now owns 523,650 shares of the specialty pharmaceutical company’s stock valued at $1,341,000 after buying an additional 68,544 shares during the period. Deutsche Bank AG purchased a new stake in Evoke Pharma during the 4th quarter valued at $452,000. 683 Capital Management LLC purchased a new stake in Evoke Pharma during the 4th quarter valued at $258,000. Finally, B. Riley Financial Inc. purchased a new stake in Evoke Pharma during the 4th quarter valued at $249,000. Institutional investors own 18.71% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This story was first published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://stocknewstimes.com/2018/03/13/q1-2018-eps-estimates-for-evoke-pharma-inc-evok-lowered-by-b-riley.html.
Evoke Pharma Company Profile
Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.